Biovica signs significant work order for TKa testing services
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Biovica, active in blood-based cancer monitoring, has signed a work order with a value of 2.2 MSEK. This is the company’s largest single work order to date for TKa testing services within its Pharma Services business. The work order is signed with a US-based biotech company focused on next-generation CDK inhibitors, which since last week has a Master Service Agreement (MSA) with Biovica.
Biovica will provide TKa testing services from its US CAP/CLIA lab for a multicenter phase I/II dose-escalation and expansion clinical study evaluating a next-generation CDK-inhibitor treatment in solid tumors.
“We are excited about this collaboration. It adds to our list of orders with a high sample number and thus shows the growing use of our TKa assay in large clinical studies. This increases the likelihood of TKa being validated as a companion biomarker for patient treatment monitoring and optimization”, said Anders Rylander, CEO of Biovica.